Mcdaniel Terry & Co. Acquires 2,737 Shares of Becton, Dickinson and Company (NYSE:BDX)

Mcdaniel Terry & Co. raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 85,383 shares of the medical instruments supplier’s stock after purchasing an additional 2,737 shares during the quarter. Becton, Dickinson and Company makes up approximately 1.7% of Mcdaniel Terry & Co.’s portfolio, making the stock its 26th largest holding. Mcdaniel Terry & Co.’s holdings in Becton, Dickinson and Company were worth $20,586,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. WR Wealth Planners LLC lifted its holdings in Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after purchasing an additional 42 shares during the last quarter. Clear Creek Financial Management LLC lifted its holdings in Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Central Pacific Bank Trust Division lifted its holdings in Becton, Dickinson and Company by 22.5% during the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares during the last quarter. Finally, Capital Advisors Ltd. LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 48 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 0.8 %

Shares of NYSE BDX opened at $238.62 on Friday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The firm’s 50 day simple moving average is $237.33 and its two-hundred day simple moving average is $235.16. The stock has a market capitalization of $68.96 billion, a P/E ratio of 52.56, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same period last year, the business earned $2.96 earnings per share. The business’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BDX. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.